Dec 14 (Reuters) - All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent (CTLT.N), opens new tab had been fulfilled ...

Novo Nordisk's stock declined 22% over the past six months, influenced by competitive pressures and supply constraints. Eli Lilly's Zepbound is rapidly gaining market share, challenging Novo's ...

The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of Novo Nordisk, one of the largest pharmaceutical companies, would pay $ ...

Novo Nordisk’s (NVO) (OTCPK:NONOF) contract with Swiss medical device maker Ypsomed (OTCPK:YPHDF) includes a deal to supply injection pens for Danish drugmaker’s next-gen obesity therapy ...

Novo Nordisk NVO shares have lost 25.1% in the past three months compared with the industry’s decline of 17.7%. The company has also underperformed the sector and the S&P 500 during the same ...

Novo Erases 2024 Gain, Wiping Out $210 Billion in Value Rivalry, supply constraints weigh on obesity drugmaker Danish firm remains Europe’s most valuable, ahead of LVMH ...

Over the last couple of years, Danish company Novo Nordisk (NYSE: NVO) has evolved from a relatively obscure pharmaceutical business to perhaps the biggest rising star in healthcare. The company's ...

LONDON, Nov 22 (Reuters) - Swiss medical technology company Ypsomed's (YPSN.S), opens new tab contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next ...

Novo Nordisk continues to witness strong growth across its portfolio of diabetes and obesity care medications. The company's tailwinds include expanded indications and new geographic markets. Its ...

Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in unlocking a big, fast-growing market for its blockbuster franchise.

As Sen. Bernie Sanders (I-Vt.) noted in a September Senate hearing, Wegovy, made by Novo Nordisk, is sold for $265 in Canada, $186 in Denmark, $137 in Germany, and just $92 in the United Kingdom.

Several existing investors—including RA Capital Management and Novo Holdings—also participated in the round. Adcendo will use the funds to develop and expand its early-stage ADC programs ...